Supplementary Figure 2 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
posted on 2023-03-31, 17:42authored byMatthew J. Brauer, Guanglei Zhuang, Maike Schmidt, Jenny Yao, Xiumin Wu, Joshua S. Kaminker, Stefanie S. Jurinka, Ganesh Kolumam, Alicia S. Chung, Adrian Jubb, Zora Modrusan, Tomoko Ozawa, C. David James, Heidi Phillips, Benjamin Haley, Rachel N.W. Tam, Anne C. Clermont, Jason H. Cheng, Sherry X. Yang, Sandra M. Swain, Daniel Chen, Stefan J. Scherer, Hartmut Koeppen, Ru-Fang Yeh, Peng Yue, Jean-Philippe Stephan, Priti Hegde, Napoleone Ferrara, Mallika Singh, Carlos Bais
PDF file - 708K, Fig S2A. Histological evidence for the in vivo activity of VEGF pathway inhibitors in MDA-MB-231 tumors. Fig S2B. In vivo VEGF blockade or VEGFR-2 downstream signaling inhibition induces consistent downregulation of proxVDV genes. Fig S2C. The proxVDV gene ESM1 is an in vivo VEGF target specifically expressed in tumor-associated vasculature